ORKA

Oruka Therapeutics, Inc. (ORKA) - Q2 2025 10-Q Summary

Business Context and Reporting Period

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. The company operates as a single reportable segment. This report covers the quarterly period ended June 30, 2025. The company was formed via a reverse recapitalization in August 2024 and is headquartered in Menlo Park, California.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by 32% ($6.9 million) in Q2 2025 compared to Q2 2024, and by 89% ($25.2 million) on a year-to-date basis. This increase is driven by higher personnel-related costs, increased stock-based compensation, and expanded external research and development activities.
• Net Loss: Net loss increased by 10% ($2.3 million) in Q2 2025 compared to Q2 2024. On a year-to-date basis, the net loss increased by 55% ($16.3 million) compared to the period from inception to June 30, 2024.
• Interest Income: The company recognized $3.9 million in interest income for Q2 2025, compared to $0 in Q2 2024, due to the investment of capital raised in late 2024.
• Related Party Transactions: Related party expenses in R&D decreased significantly in Q2 2025 ($4.3 million) compared to Q2 2024 ($15.4 million), primarily due to the timing of milestone payments and research initiation fees recognized in the prior year.

Guidance, Outlook, and Risks

• Liquidity: Management expects existing cash, cash equivalents, and marketable securities ($351.5 million) to be sufficient to fund operating plans for at least twelve months from the filing date.
• Clinical Progress:
  • ORKA-001 (IL-23p19): Dosed the first patient in a Phase 2a clinical trial (EVERLAST-A) in moderate-to-severe psoriasis in Q3 2025. Interim Phase 1 data is expected at the EADV Congress in September 2025.
  • ORKA-002 (IL-17A/F): Initiated dosing of healthy volunteers in a Phase 1 trial in Q2 2025. Interim data expected around year-end 2025.
• Outlook: The company anticipates continued significant increases in R&D and G&A expenses as it advances clinical trials and expands its organization. No revenue is expected from product sales in the foreseeable future.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital to fund operations, reliance on third-party manufacturers (including WuXi Biologics, subject to potential U.S. legislative restrictions), and potential regulatory delays. The company also faces risks related to the "One Big Beautiful Bill Act" signed in July 2025, which it is currently evaluating.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $351.5 million liquidity position against the projected burn rate of approximately $44 million per six months.
• Clinical Milestones: Monitor the upcoming release of Phase 1 interim data for ORKA-001 in September 2025 and the initiation of Phase 2 data readouts.
• Related Party Obligations: Review the terms of the Option and License Agreements with Paragon Therapeutics and Paruka, specifically regarding future milestone payments (up to $12 million clinical and $10 million regulatory per program) and royalty obligations.
• Manufacturing Risks: Assess the impact of potential U.S. legislation (e.g., BIOSECURE Act) on the company's reliance on foreign contract manufacturing organizations.
• Dilution: Note the significant number of shares reserved for future issuance (approx. 30.9 million), including options, warrants, and convertible preferred stock, which could impact future share count.